News
- Author:
- Will Pass
Publish date: January 14, 2020
Patients with high-risk disease who underwent prostatectomy also reported worse sexual function at every time point over 5 years.
News
- Author:
- Will Pass
Publish date: January 9, 2020
The sensitivity of circulating tumor DNA for recurrence was 66.0%, compared with 31.9% for carcinoembryonic antigen, in an observational study invo...
News
- Author:
- Will Pass
Publish date: January 7, 2020
In males but not females, hyperinsulinemia, insulin resistance, and metabolic syndrome are independently associated with a higher risk of Barrett’s...
News
- Author:
- Will Pass
Publish date: January 6, 2020
The update offers best practice advice for a range of clinical scenarios based on published evidence.
News
- Author:
- Will Pass
Publish date: January 3, 2020
The guidelines are the first of their kind to be published in the United States.
News
- Author:
- Will Pass
Publish date: January 2, 2020
Investigators divided muscle-invasive bladder cancer into six molecular classes based on disease factors and those consensus classes predicted over...
News
- Author:
- Will Pass
Publish date: December 26, 2019
SAN ANTONIO – The plasmaMATCH trial showed that gene level agreement between ctDNA results measured by digital PCR versus sequencing was as high as...
News
- Author:
- Will Pass
Publish date: December 20, 2019
SAN ANTONIO – When plasma and tumor tissue samples were taken within 60 days of one another, sensitivity of ctDNA testing was 98% for digital dropl...
News
- Author:
- Will Pass
Publish date: December 20, 2019
SAN ANTONIO – Platinum-based chemotherapy was associated with an 18% pCR rate, compared with 26% for standard AC among newly diagnosed HER2-negativ...
News
- Author:
- Will Pass
Publish date: December 19, 2019
In TIVO-3, a phase 3 trial involving 350 patients with metastatic RCC who had been treated with two or more systemic therapies, patients in the tiv...
News
- Author:
- Will Pass
Publish date: December 17, 2019
SAN ANTONIO - Among patients with TNBC who were treated with weekly nab-paclitaxel, 60.4% achieved pCR, compared with 50.0% who were treated with n...
News
- Author:
- Will Pass
Publish date: December 14, 2019
SAN ANTONIO – Results from large meta-analysis are expected to alter the American Joint Committee on Cancer (AJCC) staging standards in breast canc...
News
- Author:
- Will Pass
Publish date: December 13, 2019
The machine learning validation study was based on two previous case-control trials, BEST2 and BOOST.
News
- Author:
- Will Pass
Publish date: December 13, 2019
SAN ANTONIO - In a phase 3 trial of 585 women with triple-negative breast cancer, 5-year disease free survival was 86.26% in the capecitabine group...
News
- Author:
- Will Pass
Publish date: December 12, 2019
SAN ANTONIO – There was no statistically significant difference in 10-year ipsilateral breast tumor recurrence between those who received accelerat...
